Stock Analysis

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be ¥60.00

The board of Kissei Pharmaceutical Co., Ltd. (TSE:4547) has announced that it will pay a dividend of ¥60.00 per share on the 25th of June. This takes the annual payment to 2.6% of the current stock price, which is about average for the industry.

Advertisement

Kissei Pharmaceutical's Projected Earnings Seem Likely To Cover Future Distributions

Unless the payments are sustainable, the dividend yield doesn't mean too much. However, based ont he last payment, Kissei Pharmaceutical was earning enough to cover the dividend pretty comfortably. The business is earning enough to make the dividend feasible, but the cash payout ratio of 90% shows that most of the cash is going back to the shareholders, which could constrain growth prospects going forward.

Over the next year, EPS is forecast to expand by 2.6%. If the dividend continues on this path, the payout ratio could be 36% by next year, which we think can be pretty sustainable going forward.

historic-dividend
TSE:4547 Historic Dividend December 3rd 2025

Check out our latest analysis for Kissei Pharmaceutical

Kissei Pharmaceutical Has A Solid Track Record

The company has been paying a dividend for a long time, and it has been quite stable which gives us confidence in the future dividend potential. The annual payment during the last 10 years was ¥42.00 in 2015, and the most recent fiscal year payment was ¥120.00. This means that it has been growing its distributions at 11% per annum over that time. Rapidly growing dividends for a long time is a very valuable feature for an income stock.

The Dividend Looks Likely To Grow

Investors could be attracted to the stock based on the quality of its payment history. It's encouraging to see that Kissei Pharmaceutical has been growing its earnings per share at 26% a year over the past five years. Earnings per share is growing at a solid clip, and the payout ratio is low which we think is an ideal combination in a dividend stock as the company can quite easily raise the dividend in the future.

Our Thoughts On Kissei Pharmaceutical's Dividend

In summary, it's great to see that the company can raise the dividend and keep it in a sustainable range. On the plus side, the dividend looks sustainable by most measures but it is let down by the lack of cash flows. The payment isn't stellar, but it could make a decent addition to a dividend portfolio.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. However, there are other things to consider for investors when analysing stock performance. Case in point: We've spotted 2 warning signs for Kissei Pharmaceutical (of which 1 shouldn't be ignored!) you should know about. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.

Valuation is complex, but we're here to simplify it.

Discover if Kissei Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4547

Kissei Pharmaceutical

Researches, develops, manufactures, and sells pharmaceutical products primarily in Japan.

Excellent balance sheet established dividend payer.

Advertisement

Weekly Picks

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.4% undervalued
35 users have followed this narrative
6 users have commented on this narrative
10 users have liked this narrative
RO
Robbo
FID logo
Robbo on Fiducian Group ·

Fiducian: Compliance Clouds or Value Opportunity?

Fair Value:AU$126.1% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
WVVI logo
woodworthfund on Willamette Valley Vineyards ·

Willamette Valley Vineyards (WVVI): Not-So-Great Value

Fair Value:US$244.5% overvalued
6 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

FU
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6411.4% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
GOOGL logo
MarkoVT on Alphabet ·

Positioned globally, partnered locally

Fair Value:US$390.1918.1% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JO
JohnJ
WLN logo
JohnJ on Worldline ·

When will fraudsters be investigated in depth. Fraud was ongoing in France too.

Fair Value:€0.5190.0% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
113 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3928.3% undervalued
952 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3406.0% undervalued
148 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative